Herantis Pharma Oyj (HRTIS.HE)
Herantis Pharma Oyj operates in the Biotechnology industry of the Healthcare sector, headquartered in Espoo, UU, FI. The stock last traded at $1.65, down 1.08% on the session, giving a market capitalisation of $43.8M. Its beta of 0.60 implies it has historically moved less than the broad market.
Herantis Pharma Oyj, a biotechnology company founded in Espoo, Finland, in 2008, is dedicated to developing innovative, disease-modifying CDNF-based treatments for Parkinson's disease (PD). Its pipeline features two key assets: HER-096, an advanced small, synthetic chemical peptidomimetic (a modified version of the active CDNF parent molecule) which is in preclinical stages as an xCDNF candidate for Parkinson's and other neurodegenerative conditions; and recombinant human Cerebral Dopamine Neurotrophic Factor (rhCDNF), a biological protein currently in Phase I clinical trials for patients with PD.
Herantis Pharma Oyj is most often compared with the following Healthcare names: